Nymox Pharma's (NYMX) Phase 2 NX03-0040 Trial of Fexapotide Triflutate Meets Primary Endpoint
Tweet Send to a Friend
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
